It's hard to remember the last time the Street was really hot on Forest Labs (FRX). Although this company has shown a pretty surprising resilience and an uncanny ability to find good licensing deals, analysts seemingly can't move past the admittedly huge ramifications of key drug Lexapro going generic. It's not as though Forest Labs has been caught flat-footed, though, and there seems to be value in Forest's pipeline than the Street can see.
Click here for more:
Investors Can Still Benefit From Street's Doubts About Forest Labs
No comments:
Post a Comment